share_log

T2 Biosystems | S-1: General form for registration of securities under the Securities Act of 1933

SEC announcement ·  Apr 22 17:17
Summary by Moomoo AI
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on April 22, 2024, for a Registration Statement under the Securities Act of 1933. This filing indicates T2 Biosystems' intent to offer shares of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock. The offering is to commence as soon as practicable after the Registration Statement is declared effective. T2 Biosystems, based in Lexington, Massachusetts, is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol 'TTOO.' The company has engaged a placement agent to use reasonable best efforts to solicit offers to purchase the securities. The offering...Show More
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on April 22, 2024, for a Registration Statement under the Securities Act of 1933. This filing indicates T2 Biosystems' intent to offer shares of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock. The offering is to commence as soon as practicable after the Registration Statement is declared effective. T2 Biosystems, based in Lexington, Massachusetts, is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol 'TTOO.' The company has engaged a placement agent to use reasonable best efforts to solicit offers to purchase the securities. The offering includes provisions for the sale of pre-funded warrants to investors who would otherwise exceed beneficial ownership limits. The proceeds from the offering are intended for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close no later than 2024, subject to customary closing conditions.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more